ciprofloxacin has been researched along with Electrocardiogram QT Prolonged in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 7.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 5.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| " The patient was under amiodarone and sotalol therapy for atrial fibrillation, with no obvious QT prolongation prior to ciprofloxacin therapy." | 3.75 | Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy. ( Arnaoutoglou, C; Chrisopoulos, C; Keivanidou, A; Kirpizidis, C; Krommydas, A; Papanikolaou, G; Tsiptses, K, 2009) |
| "He had a 3." | 1.35 | Ciprofloxacin-induced Q-T interval prolongation. ( Knorr, JP; Moshfeghi, M; Sokoloski, MC, 2008) |
| "Ciprofloxacin may cause QTc prolongation and rarely torsades de pointes." | 1.32 | Ciprofloxacin-induced acquired long QT syndrome. ( Krahn, AD; Prabhakar, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, FA | 2 |
| van Weteringen, W | 1 |
| van der Sijs, H | 2 |
| Hunfeld, NGM | 1 |
| Bunge, JJH | 1 |
| de Groot, NMS | 2 |
| van den Bemt, PMLA | 2 |
| van Gelder, T | 2 |
| Monadian, N | 1 |
| Santbergen, B | 1 |
| Becker, ML | 2 |
| Broers, AEC | 1 |
| Heemskerk, C | 1 |
| Woldman, E | 1 |
| Pereboom, M | 1 |
| Van der Hoeven, R | 1 |
| Mantel-Teeuwisse, A | 1 |
| Van Gemeren, C | 1 |
| Matsuo, K | 1 |
| Fujiwara, K | 1 |
| Omuro, N | 1 |
| Kimura, I | 1 |
| Kobayashi, K | 1 |
| Yoshio, T | 1 |
| Takahara, A | 1 |
| Keivanidou, A | 1 |
| Arnaoutoglou, C | 1 |
| Krommydas, A | 1 |
| Papanikolaou, G | 1 |
| Tsiptses, K | 1 |
| Chrisopoulos, C | 1 |
| Kirpizidis, C | 1 |
| Salinas Arce, J | 1 |
| Romero, R | 1 |
| Solorzano, P | 1 |
| Werner, CR | 1 |
| Riessen, R | 1 |
| Gregor, M | 1 |
| Bitzer, M | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Kochanek, M | 1 |
| Shimabukuro-Vornhagen, A | 1 |
| Prabhakar, M | 1 |
| Krahn, AD | 1 |
| Letsas, KP | 1 |
| Sideris, A | 1 |
| Kounas, SP | 1 |
| Efremidis, M | 1 |
| Korantzopoulos, P | 1 |
| Kardaras, F | 1 |
| Wooten, JM | 1 |
| Makaryus, AN | 1 |
| Byrns, K | 1 |
| Makaryus, MN | 1 |
| Natarajan, U | 1 |
| Singer, C | 1 |
| Goldner, B | 1 |
| Tsikouris, JP | 1 |
| Peeters, MJ | 1 |
| Cox, CD | 1 |
| Meyerrose, GE | 1 |
| Seifert, CF | 1 |
| Kaźmierczak, J | 1 |
| Peregud-Pogorzelska, M | 1 |
| Rzeuski, R | 1 |
| Knorr, JP | 1 |
| Moshfeghi, M | 1 |
| Sokoloski, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB[NCT02409290] | Phase 3 | 588 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
probable or definite failure or recurrence (FoR) (NCT02409290)
Timeframe: final efficacy week (between 96 and 132 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 17 |
| Regimen C (Oral Regimen) | 4 |
| Regimen D (6-month Regimen) | 0 |
The proportion of patients with failure or recurrence (FoR) (NCT02409290)
Timeframe: 132 weeks, control regimen (arm B) using concurrent controls only
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen B (Control Regimen) | 14 |
| Regimen D (6-month Regimen) | 2 |
The proportion of patients with a favourable outcome at their last efficacy visit (NCT02409290)
Timeframe: Last efficacy visit, between 96 and 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 17 |
| Regimen B (Control Regimen) | 126 |
| Regimen C (Oral Regimen) | 152 |
| Regimen D (6-month Regimen) | 115 |
The proportion of patients with acquired drug resistance (any drug) (NCT02409290)
Timeframe: 132 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 5 |
| Regimen C (Oral Regimen) | 5 |
| Regimen D (6-month Regimen) | 3 |
The primary efficacy outcome of the STREAM Stage 2 comparison is status at Week 76 i.e. the proportion of patients with a favourable outcome at Week 76 (NCT02409290)
Timeframe: 76 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Regimen A (Long Regimen) | 0 |
| Regimen B (Control Regimen) | 133 |
| Regimen C (Oral Regimen) | 162 |
| Regimen D (6-month Regimen) | 122 |
1 review available for ciprofloxacin and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Ciprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Ciprofloxacin; Electrocardiography; Female; Fl | 2017 |
1 trial available for ciprofloxacin and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; | 2006 |
14 other studies available for ciprofloxacin and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; El | 2021 |
QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factors.
Topics: Ciprofloxacin; Drug Therapy, Combination; Electrocardiography; Female; Fluconazole; Heart Rate; Huma | 2018 |
Effects of the fluoroquinolone antibacterial drug ciprofloxacin on ventricular repolarization in the halothane-anesthetized Guinea pig.
Topics: Action Potentials; Anesthesia; Animals; Anti-Bacterial Agents; Calcium Channel Blockers; Ciprofloxac | 2013 |
Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Infective Agents; Atrial Fibrillation; Ciprofloxacin; | 2009 |
A case of prolonged QT interval and torsades de pointes due to ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Long QT Syndrome; Male; Torsades de Pointes | 2010 |
[Unexpected complication following esophageal variceal hemorrhage - Case 2/2011].
Topics: Amiodarone; Anti-Bacterial Agents; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inh | 2011 |
[53-year-old woman with life-threatening complications after use of ciprofloxacin and posaconazol].
Topics: Anti-Infective Agents; Cardiopulmonary Resuscitation; Ciprofloxacin; Electrocardiography; Female; Hu | 2012 |
Moxifloxacin: new preparation. A me-too with more cardiac risks.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Approval; Fluoroquinolones; France | 2002 |
Ciprofloxacin-induced acquired long QT syndrome.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Electric Countershock; Electrocardiography; Femal | 2004 |
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.
Topics: Aged; Anti-Infective Agents; Antipsychotic Agents; Benzodiazepines; Bundle-Branch Block; Ciprofloxac | 2006 |
Drug-induced QT prolongation.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Electrocardiography; Female; Humans; Long QT Syndrome; O | 2006 |
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event?
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Electrocardiography; F | 2006 |
QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Infective Agents; Ciprofloxacin; Defibrillators, Implantable; Dru | 2007 |
Ciprofloxacin-induced Q-T interval prolongation.
Topics: Abscess; Acetamides; Adolescent; Anti-Infective Agents; Aztreonam; Bradycardia; Ciprofloxacin; Crohn | 2008 |